Comparative Pharmacology
Head-to-head clinical analysis: KISQALI versus KISQALI FEMARA CO PACK COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KISQALI versus KISQALI FEMARA CO PACK COPACKAGED.
KISQALI vs KISQALI FEMARA CO-PACK (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Kisqali (ribociclib) selectively inhibits CDK4 and CDK6, which are involved in cell cycle progression. By inhibiting these kinases, it reduces retinoblastoma protein (Rb) phosphorylation, leading to cell cycle arrest in the G1 phase and reduced proliferation of cancer cells.
Kisqali (ribociclib) is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, which blocks retinoblastoma protein phosphorylation, leading to G1 cell cycle arrest and reduced proliferation of breast cancer cells. Femara (letrozole) is a nonsteroidal aromatase inhibitor, inhibiting estrogen synthesis by blocking the conversion of androgens to estrogens. The co-pack provides combination therapy for HR+/HER2- breast cancer.
600 mg orally once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle), in combination with an aromatase inhibitor or fulvestrant.
KISQALI (ribociclib) 600 mg orally once daily for 21 consecutive days followed by 7 days off treatment in a 28-day cycle, in combination with FEMARA (letrozole) 2.5 mg orally once daily continuously.
None Documented
None Documented
Terminal half-life is approximately 32 hours (range 29-40 hours) after oral administration, supporting once-daily dosing. The long half-life allows for steady-state achievement within 8 days.
Ribociclib: 29.6–57.3 hours (mean ~48 h), supporting once-daily dosing. Letrozole: 48–60 hours, steady-state reached in 2–6 weeks.
Primarily hepatic metabolism via CYP3A4, with 69% of dose eliminated in feces (as unchanged drug and metabolites) and 23% in urine (mostly as metabolites). Unchanged ribociclib accounts for <10% of excreted drug.
Ribociclib: 69% fecal (unchanged and metabolites), 23% renal (12% unchanged). Letrozole: ~90% renal as inactive metabolite, <5% unchanged.
Category C
Category C
CDK4/6 Inhibitor Antineoplastic
CDK4/6 Inhibitor and Aromatase Inhibitor Combination Antineoplastic